Created in 1997, Hybrigenics is a bio-pharmaceutical company with a focus on research and development of new targets & therapies against proliferative cancerous or non-cancerous diseases. Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist being assessed in three indications:
prostate cancer, for use with current standards of care,
chronic lymphocytic leukaemia,
moderate to severe psoriasis.
Hybrigenics' research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the utility of proprietary patented DUB inhibitors against various cancer indications. Hybrigenics Services, a Hybrigenics subsidiary, markets very specialized scientific services to researchers in all areas of life sciences who want to identify, validate and inhibit protein interactions in animal, plant or microbiological cells.
3-5 impasse Reille